PRA Health Sciences,Inc. (NASDAQ:PRAH) Files An 8-K Entry into a Material Definitive Agreement

ME Staff 8-k
-
0

PRA Health Sciences,Inc. (NASDAQ:PRAH) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01. Entry into a Material Definitive Agreement.

On August8, 2017, PRA Health Sciences,Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) by and among the Company, the selling stockholders named therein (the “Selling Stockholders”), and Morgan Stanley& Co. LLC and Wells Fargo Securities, LLC (the “Underwriters”), relating to an underwritten offering (the “Offering”) of 10,000,000 shares (the “Shares”) of the Company’s common stock, par value $0.01 per share, to the Company’s Registration Statement on FormS-3 (File No.333-209883), filed on March2, 2016, as supplemented by the prospectus supplement dated August8, 2017. All of the Shares are being sold by the Selling Stockholders. to the Underwriting Agreement, the Underwriters purchased the Shares at a price of $74.85 per share in a transaction that was completed on August14, 2017.

The description of the Underwriting Agreement is qualified in its entirety by the terms of such agreement, which is incorporated herein by reference and attached to this report as Exhibit1.1.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

See the ExhibitIndex immediately following the pagehereto, which is incorporated herein by reference.


PRA Health Sciences, Inc. Exhibit
EX-1.1 2 a17-19118_4ex1d1.htm EX-1.1 Exhibit 1.1   Execution Version   10,…
To view the full exhibit click here

About PRA Health Sciences,Inc. (NASDAQ:PRAH)

PRA Health Sciences, Inc. is a contract research organization (CRO). The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases. The Company’s integrated services include data management, statistical analysis, clinical trial management, and regulatory and drug development consulting. The Company’s service offerings include Product Registration Services, which includes Phase IIb through III product registration trials and Phase IV trials, inclusive of post-marketing commitments and registries; Strategic Solutions, which provides Embedded Solutions and functional outsourcing services, and Early Development Services, which includes Phase I through Phase IIa clinical trials and bioanalytical laboratory services.